Antifúngicos

Terconazole is an azole antifungal agent with action on fungal cell membranes by inhibiting ergosterol biosynthesis and is used for treating vaginal yeast infections.

Voriconazole is a synthetic, lipophilic molecule that is used in the treatment of fungal infections. Voriconazole binds to ergosterol which is the major sterol in the cell wall of fungi and inhibits its synthesis, leading to cell death. This drug binds to the enzyme 14α-demethylase allowing the conversion of lanosterol into ergosterol. As a result, this binding leads to the inhibition of ergosterol synthesis, as well as other sterols that are necessary for fungal growth (e.g., squalene).

Amphotericin A is a polyene macrolide antibiotic, which is derived primarily from the soil bacterium *Streptomyces nodosus*. This compound functions by binding to ergosterol, an essential component of fungal cell membranes. This binding creates pores in the membrane, increasing its permeability and ultimately leading to cell death. Unlike its more widely used counterpart Amphotericin B, Amphotericin A is less frequently utilized but is critical in the study and understanding of antifungal activity.

Atovaquone is an antimicrobial drug that is used for the treatment of Pneumocystis jirovecii pneumonia. This drug is an analog of ubiquinone and has good in vitro activity against Toxoplasma gondii.

Abafungin is an antifungal agent and is used for treating fungal infections.

Malformin C is a cyclic pentapeptide, which is a secondary metabolite derived from certain strains of the fungus Aspergillus. Its mode of action involves disrupting cellular processes by interfering with cell division. Specifically, it is thought to affect mitotic spindle formation, leading to abnormal cell cycle progression.

21-Norrapamycin is a macrocyclic lactone antibiotic, which is derived from the bacterium Streptomyces hygroscopicus. Its chemical structure is closely related to that of rapamycin, a well-known immunosuppressant. The mode of action of 21-Norrapamycin involves the inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway. By binding to the FK506-binding protein 12 (FKBP12), it forms a complex that then inhibits mTOR, a crucial regulator of cell growth, proliferation, and survival.